Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Theriva Biologics, Inc. (TOVX) had Return on Tangible Equity of -154.32% for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-25.25M |
|
-- |
|
-- |
|
$24.05M |
|
$-24.05M |
|
$0.31M |
|
$-23.74M |
|
$-23.74M |
|
$-23.74M |
|
$-23.74M |
|
$-23.74M |
|
$-23.74M |
|
$-24.05M |
|
$-23.94M |
|
12.14M |
|
12.14M |
|
$-2.08 |
|
$-2.08 |
|
| Balance Sheet Financials | |
$17.47M |
|
$0.22M |
|
$20.77M |
|
$38.24M |
|
$10.01M |
|
$1.67M |
|
$12.84M |
|
$22.86M |
|
$15.38M |
|
$15.38M |
|
$15.38M |
|
35.69M |
|
| Cash Flow Statement Financials | |
$-16.67M |
|
$-0.04M |
|
$18.19M |
|
$11.71M |
|
$13.10M |
|
$1.40M |
|
$0.65M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.74 |
|
-- |
|
-- |
|
0.10 |
|
0.11 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-16.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-154.32% |
|
|
Return on Tangible Equity |
-154.32% |
-62.08% |
|
-139.20% |
|
$0.43 |
|
$-1.38 |
|
$-1.37 |
|